Table 3.
Predictors | Levels | Symptom Domain |
Activity Domain |
Impacts Domain |
Total Domain |
---|---|---|---|---|---|
Region of residence | Rural | 2.56 * | 2.98 | 3.99 * | 4.77 * |
(2.56–2.56) | (0.25–1.46) | (3.43–5.87) | (3.06–5.54) | ||
Urban | 0 | 0 | 0 | 0 | |
Sex group | Female | 2.98 | 3.82 | 2.43 * | |
(0.17–3.97) | (0.16–4.22) | (1.27–3.86) | |||
Male | 0 | 0 | 0 | ||
Having comorbidity | Yes | 8.74 * | 15.84 * | 4.40 | 7.22 * |
(4.23–14.65) | (3.73–30.20) | (−0.07–9.83) | (3.12–17.57) | ||
No | 0 | 0 | 0 | 0 | |
Vaccination status | Fully vaccinated | −2.98 * | −3.99 * | −3.96 * | |
(−8.68–1.61) | (−5.90–3.15) | (−5.87–2.88) | |||
Partially vaccinated | −2.98 * | −3.84 * | −3.00 | ||
(−7.86–2.83) | (−4.32–0.25) | (−5.15–0.61) | |||
Unvaccinated | 0 | 0 | 0 | ||
Disease severity | Moderate/Severe | 19.45 * | 32.62 * | 15.00 * | 21.27 * |
(15.65–29.09) | (22.21–38.95) | (10.51–19.42) | (16.22–24.51) | ||
Mild | 9.71 * | 2.09 | 3.97 * | 5.18 * | |
(9.71–9.71) | (0.51–4.30) | (2.99–4.31) | (4.74–6.43) | ||
Asymptomatic | 0 | 0 | 0 | 0 |
Values in brackets denote 95% confidence interval. The * indicates significant difference.